{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:11:51Z","timestamp":1767136311581,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd013106","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000}}],"reference-count":189,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013106.pub2","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T12:27:01Z","timestamp":1561465621000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B"],"prefix":"10.1002","author":[{"given":"Ning","family":"Liang","sequence":"first","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; Bei San Huan Dong Lu 11, Chaoyang District Beijing China 100029"},{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De Zhao","family":"Kong","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Copenhagen Denmark"},{"name":"Liaoning University of Traditional Chinese Medicine; Chong Shan East Road 79 Shenyang Liaoning Province China 110032"},{"name":"The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine; Department of Cardiology; Beiling Street 33 Shenyang Liaoning Province China 110032"},{"name":"Liaoning University of Traditional Chinese Medicine; Co-construct Key Laboratory of Theory of Visceral Manifestations and Applications; Chong Shan East Road 79 Shenyang Liaoning Province China 110032"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Li","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; Bei San Huan Dong Lu 11, Chaoyang District Beijing China 100029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si Si","family":"Ma","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; Bei San Huan Dong Lu 11, Chaoyang District Beijing China 100029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; Bei San Huan Dong Lu 11, Chaoyang District Beijing China 100029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrinka","family":"Nikolova","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janus C","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Copenhagen Denmark"},{"name":"Holbaek Hospital; Department of Cardiology; Holbaek Denmark 4300"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; Bei San Huan Dong Lu 11, Chaoyang District Beijing China 100029"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0001|cit1","first-page":"229, 231","article-title":"Clinical observation on the therapeutic efficacy of matrine on chronic hepatitis B with hyperbilirubinemia","volume":"32","author":"Deng","year":"2010","journal-title":"International Journal of Traditional Chinese Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0002|cit2","first-page":"259","article-title":"Clinical study of the interferon a-2b combined with kurorinone in the treatment of chronic hepatitis B","volume":"22","author":"Huang","year":"2004","journal-title":"Chinese Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0003|cit3","first-page":"1100","article-title":"Clinical study of treatment of chronic hepatitis B with kurorinone combined with thymosin","volume":"30","author":"Huang","year":"2005","journal-title":"Medical Journal of Chinese People's Liberation Army"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0004|cit4","first-page":"40","article-title":"Ku shen su capsules for treating chronic hepatitis B","volume":"14","author":"Liang","year":"2006","journal-title":"Chinese Journal of Trauma and Disability Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013106.pub2-BIB0005|cit5","first-page":"986","article-title":"Clinical observation of adefovir dipivoxil in the treatment of hepatitis B patients with HBeAg positive","volume":"20","author":"Wang","year":"2013","journal-title":"Chinese Journal of Primary Medicine Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0006|cit6","first-page":"36","article-title":"Matrine injections combined with liver protective drugs for children with chronic hepatitis B","volume":"27","author":"Xi","year":"2010","journal-title":"Journal of Gansu College of Traditional Chinese Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0007|cit7","first-page":"103","article-title":"Clinic study of treating chronic hepatitis B and cirrhosis with matrine and glucose injection","volume":"4","author":"Xu","year":"2003","journal-title":"China Synthesis Medicine"},{"issue":"2017","key":"10.1002\/14651858.CD013106.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1051\/bioconf\/20170801029","article-title":"Investigation of therapeutic effect of Longchai formula granule on chronic hepatitis B patients: a double-blind, controlled and randomized clinical trial","volume":"8","author":"Yan","year":"2017","journal-title":"BIO Web of Conferences"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0009|cit9","volume-title":"Clinical Significance of Serum HBsAg Quantitative Detection in Patients with Chronic Hepatitis B and the Controlled Study on the Treatment Effects on HBsAg between Lamivudine and Oxymatrine [Masters dissertation]","author":"Zhang","year":"2007"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0010|cit10","first-page":"121-3, 126","article-title":"Effect of lamivudine combined with matrine on treating children with chronic hepatitis B","volume":"3","author":"Zhang","year":"2011","journal-title":"Research of Integrated Traditional Chinese and Western Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0011|cit11","first-page":"58","article-title":"The inhibition of kurarinone on hepatitis B","volume":"28","author":"Cao","year":"2007","journal-title":"Chinese Journal of Biochemical Pharmaceutics"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2893.2000.00216.x","article-title":"A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B","volume":"7","author":"Chen","year":"2000","journal-title":"Journal of Viral Hepatitis"},{"issue":"9","key":"10.1002\/14651858.CD013106.pub2-BIB0013|cit13","first-page":"117","article-title":"Clinical observation on treatment of chronic hepatitis B with ku shen su injection","volume":"17","author":"Chen","year":"2001","journal-title":"Occupation and Health"},{"issue":"112","key":"10.1002\/14651858.CD013106.pub2-BIB0014|cit14","first-page":"11744","article-title":"Clinical observation of oxymatrine in the treatment of chronic hepatitis B in children","volume":"10","author":"Chen","year":"2004","journal-title":"Chinese Journal of Clinical Medicine Research"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0015|cit15","unstructured":"Chen LY Clinical observation of adefovir dipivoxil in the treatment of chronic hepatitis B The First National Conference on Difficult and Serious Liver Diseases, the Fourth National Annual Conference on Artificial Liver and Blood Purification; 2008 Sep 3-5; Nanchang (Jiangxi, China) 2008"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0016|cit16","first-page":"21","article-title":"Comparison of the efficacy of Bortali injection and a-interferon in the treatment of chronic hepatitis B","volume":"13","author":"Cui","year":"2006","journal-title":"Chinese Journal of Rural Medicine and Pharmacy"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0017|cit17","first-page":"80","article-title":"Clinical study of oxymatrine combined with interferon in the treatment of chronic hepatitis B","volume":"26","author":"Gong","year":"2010","journal-title":"Nei Mongol Journal of Traditional Chinese Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0018|cit18","first-page":"429","article-title":"Therapeutic effect of thymosin \u03b11 combined with oxymatrine capsule on lamivudine-resistant chronic hepatitis B","volume":"22","author":"Hu","year":"2006","journal-title":"Journal of Clinical Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0019|cit19","first-page":"312","article-title":"Clinical observation of lamivudine combined with oxymatrine in the treatment of chronic hepatitis B","volume":"11","author":"Jiang","year":"2013","journal-title":"Seek Medical and Ask the Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0020|cit20","first-page":"272","article-title":"Clinical study on matrine for the treatment of chronic hepatitis B","volume":"24","author":"Jiao","year":"2003","journal-title":"Medical Journal of National Defending Forces in Northwest China"},{"issue":"8","key":"10.1002\/14651858.CD013106.pub2-BIB0021|cit21","first-page":"139","article-title":"Cost effectiveness analysis of three methods in the treatment of chronic viral hepatitis B","volume":"20","author":"Jin","year":"2008","journal-title":"Strait Pharmaceutical Journal"},{"issue":"17","key":"10.1002\/14651858.CD013106.pub2-BIB0022|cit22","first-page":"53","article-title":"Long-term efficacy of oxymatrine in the treatment of chronic hepatitis B","volume":"31","author":"Li","year":"2004","journal-title":"Central Plains Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0023|cit23","first-page":"337","article-title":"Clinical observation on treatment of chronic hepatitis B with Tianqing Fuxin","volume":"32","author":"Li","year":"2006","journal-title":"Journal of Modern Clinical Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0024|cit24","first-page":"105","article-title":"Comparison of the curative effect of the oxymatrine and \u03b1-interferon","volume":"19","author":"Li","year":"2006","journal-title":"Journal of Handan Medical College"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0025|cit25","unstructured":"Li L Liao QH Clinical observation on 196 cases of chronic hepatitis B treated with oxymatrine The 9th Zhejiang Provincial Conference on Integrated Traditional and Western Medicine for Liver Diseases; 2006 Jun 1; Pujiang (Zhejiang, China) 2006 117 20"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0026|cit26","first-page":"152","article-title":"Comparison of the efficacy of thymosin \u03b11 and oxymatrine capsules in the treatment of hepatitis B virus carriers during immune tolerance","volume":"26","author":"Li","year":"2013","journal-title":"Medical Information"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0027|cit27","first-page":"71","article-title":"Clinical observation of matrine for anti-fibrosis","volume":"11","author":"Liu","year":"2001","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0028|cit28","first-page":"38","article-title":"Treatment of 28 cases of chronic hepatitis B with oxymatrine combined with acyclovir","volume":"11","author":"Liu","year":"2001","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0029|cit29","unstructured":"Liu ZS Xu JH Zhao GL Li GC Observation on 40 cases of chronic hepatitis B treated with oxymatrine 2002 National Conference on Integrative Medicine for Liver Diseases; 2002 Aug 9-11; Guiyang (Guizhou, China) 2002 73 4"},{"issue":"8","key":"10.1002\/14651858.CD013106.pub2-BIB0030|cit30","first-page":"700","article-title":"Clinical study on treatment of chronic hepatitis B by kurarinone combined with interferon \u03b1-1b","volume":"28","author":"Pan","year":"2005","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0031|cit31","first-page":"829","article-title":"Curative effect observation of 90 cases of chronic hepatitis B treated with oxymatrine","volume":"38","author":"Qin","year":"2003","journal-title":"Journal of Zhengzhou University (Medical Sciences)"},{"issue":"9","key":"10.1002\/14651858.CD013106.pub2-BIB0032|cit32","first-page":"409","article-title":"Effects of oxymatrine on the patients with chronic hepatitis B","volume":"12","author":"She","year":"2000","journal-title":"Ningbo Yi Xue"},{"issue":"23","key":"10.1002\/14651858.CD013106.pub2-BIB0033|cit33","first-page":"66","article-title":"Forty-six cases of chronic hepatitis B treated with acupoint injection of matrine","volume":"3","author":"Song","year":"2008","journal-title":"China Foreign Medical Treatment"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0034|cit34","unstructured":"Su GY Comparison of clinical efficacy between bicyclol and oxymatrine in the treatment of chronic hepatitis B Compilation of the 2006 Conference on Infectious Diseases and Liver Diseases in Zhejiang Province; 2006 Oct 1; Ningbo (Zhejiang, China) 2006 238 9"},{"issue":"10","key":"10.1002\/14651858.CD013106.pub2-BIB0035|cit35","first-page":"17","article-title":"Kurorinone combined with thymus peptide in the treatment of chronic hepatitis B","volume":"26","author":"Sui","year":"2006","journal-title":"Clinical Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0036|cit36","first-page":"40","article-title":"Clinical observation of oxymatrine in the treatment of chronic hepatitis B","volume":"16","author":"Sun","year":"2002","journal-title":"Chinese Journal of Urban and Rural Industrial Hygiene"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0037|cit37","unstructured":"Sun BJ Clinical study of adefovir dipivoxil in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B The 10th National Conference on Liver Diseases and the 10th Anniversary of the Chinese Journal of Liver Diseases; 2006 May 11-15; Dalian (Liaoning, China) 2006 276"},{"issue":"10","key":"10.1002\/14651858.CD013106.pub2-BIB0038|cit38","first-page":"945","article-title":"Clinical observation on treatment of 52 cases of chronic hepatitis B in children with oxymatrine","volume":"3","author":"Tang","year":"2005","journal-title":"Chinese Journal of Current Clinical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0039|cit39","first-page":"8","article-title":"Research of medical treatment novel program on the chronic viral hepatitis B","volume":"30","author":"Wang","year":"2001","journal-title":"Bulletin of Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0040|cit40","first-page":"10","article-title":"Therapeutic effect of oxymatrine injection on chronic hepatitis B","volume":"3","author":"Wang","year":"2003","journal-title":"Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0041|cit41","first-page":"20","article-title":"Comparison of short-term effects of lamivudine combined with liver protective tablets or matrine in the treatment of chronic hepatitis B","volume":"28","author":"Wang","year":"2006","journal-title":"Journal of Guiyang College of Traditional Chinese Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0042|cit42","first-page":"366","article-title":"Observing the efficacy of oxymartine and Interferon together treating 36 patients with chronic hepatitis B","volume":"3","author":"Wang","year":"2006","journal-title":"Drug Evaluation"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0043|cit43","first-page":"239","article-title":"Therapeutic effect of adefovir dipivoxil on 72 patients with chronic hepatitis B","volume":"20","author":"Wang","year":"2007","journal-title":"Infectious Disease Information"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0044|cit44","first-page":"219","article-title":"Clinical efficacy of matrine injection in the treatment of chronic hepatitis B","volume":"6","author":"Wang","year":"2009","journal-title":"Laboratory Medicine and Clinic"},{"issue":"16","key":"10.1002\/14651858.CD013106.pub2-BIB0045|cit45","first-page":"20","article-title":"Clinical observation of high dose hepatitis B vaccine combined with vaccae in the treatment of chronic HBV carriers","volume":"4","author":"Wu","year":"2009","journal-title":"China Healthcare Innovation"},{"issue":"24","key":"10.1002\/14651858.CD013106.pub2-BIB0046|cit46","first-page":"2631","article-title":"Remote effect of oxymatrine on chronic hepatitis B","volume":"12","author":"Xia","year":"2003","journal-title":"Modern Journal of Integrated Traditional Chinese and Western Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0047|cit47","first-page":"44","article-title":"The ester and oxymatrine treatment of chronic hepatitis B","volume":"16","author":"Xiao","year":"2013","journal-title":"Medical Aesthetics and Cosmetology"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0048|cit48","first-page":"36","article-title":"Clinical study of oxymatrine combined with adenosine monophosphate in the treatment of chronic hepatitis B","volume":"20","author":"Xie","year":"2003","journal-title":"Tianjin Journal of Traditional Chinese Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0049|cit49","first-page":"107","article-title":"Clinical efficacy of aspartate ornithine in the treatment of hepatitis B cirrhosis","volume":"26","author":"Xue","year":"2016","journal-title":"China Health Care Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0050|cit50","first-page":"22","article-title":"Clinical observation of oxymatrine against liver fibrosis","volume":"2","author":"Yang","year":"2005","journal-title":"Anti-Infection Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0051|cit51","first-page":"280","article-title":"A clinical research on oxymatrine for the treatment of chronic hepatitis B","volume":"10","author":"Yu","year":"2002","journal-title":"Chinese Journal of Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0052|cit52","first-page":"226","article-title":"Treatment of 89 cases of chronic hepatitis B with Bortalin injection","volume":"11","author":"Zhang","year":"2001","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0053|cit53","first-page":"8","article-title":"Therapeutic effect of interferon combined with oxymatrine on chronic hepatitis B","volume":"11","author":"Zhong","year":"2008","journal-title":"China Foreign Medical Treatment"},{"issue":"7","key":"10.1002\/14651858.CD013106.pub2-BIB0054|cit54","first-page":"96-7, 120","article-title":"The clinical effects of glutathione auxiliary in the treatment of chronic hepatitis B liver fibrosis","volume":"4","author":"Zhou","year":"2014","journal-title":"China Medicine and Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"9912","key":"10.1002\/14651858.CD013106.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(13)62297-7","article-title":"Increasing value and reducing waste in biomedical research regulation and management","volume":"383","author":"Al-Shahi Salman","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0057|cit57","first-page":"1142","article-title":"Patient concerns regarding chronic hepatitis B and C infection","volume":"14","author":"Alizadeh","year":"2008","journal-title":"Eastern Mediterranean Health Journal"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD013106.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ije\/dyn188","article-title":"Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses","volume":"38","author":"Brok","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"7572","key":"10.1002\/14651858.CD013106.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cpt.536","article-title":"Comment on: \"Cell therapy for heart disease: trial sequential analyses of two Cochrane Reviews\"","volume":"102","author":"Castellini","year":"2017","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"110","key":"10.1002\/14651858.CD013106.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-018-0770-1","article-title":"Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis","volume":"7","author":"Castellini","year":"2018","journal-title":"Systematic Reviews"},{"issue":"9683","key":"10.1002\/14651858.CD013106.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"},{"issue":"9912","key":"10.1002\/14651858.CD013106.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","article-title":"How to increase value and reduce waste when research priorities are set","volume":"383","author":"Chalmers","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/B978-0-444-53741-6.00048-9","article-title":"Treatments used in complementary and alternative medicine","volume":"33","author":"Chan","year":"2011","journal-title":"Side Effects of Drugs Annual"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0068|cit68","volume-title":"Dictionary of Traditional Chinese Medicine","author":"Nanjing University of Traditional Chinese Medicine","year":"2006"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0069|cit69","volume-title":"The Pharmacopoeia of People's Republic of China","author":"The Tenth Pharmacopoeia Commission","year":"2015"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0071|cit71","first-page":"62","article-title":"Viral hepatitis prevention and treatment guideline","volume":"40","author":"Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology","year":"2001","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0072|cit72","first-page":"881","article-title":"The guideline of prevention and treatment for chronic hepatitis B (2005 version)","volume":"13","author":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases","year":"2005","journal-title":"Chinese Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0073|cit73","first-page":"1","article-title":"The guideline of prevention and treatment for chronic hepatitis B (2010 version)","volume":"12","author":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases","year":"2011","journal-title":"Chinese Journal of Preventive Medicine"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0074|cit74","first-page":"A3513","article-title":"Hepatitis B; sometimes co-infection with hepatitis D","volume":"155","author":"Derikx","year":"2011","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1046\/j.1440-1746.2002.02885.x","article-title":"Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine","volume":"17","author":"Dong","year":"2002","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","author":"European Association for the Study of the Liver","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"7109","key":"10.1002\/14651858.CD013106.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/nop2.100","article-title":"A qualitative study on individual experiences of chronic hepatitis B patients","volume":"4","author":"Ezbarami","year":"2017","journal-title":"Nursing Open"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/2340521","article-title":"On the interpretation of X2 from contingency tables, and the calculation of P","volume":"85","author":"Fisher","year":"1922","journal-title":"Journal of the Royal Statistical Society"},{"issue":"25","key":"10.1002\/14651858.CD013106.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Gartlehner G Nussbaumer-Streit B Wagner G Patel S Swinson-Evans T Dobrescu A Increased risks for random errors are common in outcomes graded as high certainty of evidence Journal of Clinical Epidemiology 2019 50 9 10.1016\/j.jclinepi.2018.10.009","DOI":"10.1016\/j.jclinepi.2018.10.009"},{"issue":"9913","key":"10.1002\/14651858.CD013106.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(13)62228-X","article-title":"Reducing waste from incomplete or unusable reports of biomedical research","volume":"383","author":"Glasziou","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/ije\/dyi206","article-title":"A mathematical model to estimate global hepatitis B disease burden and vaccination impact","volume":"34","author":"Goldstein","year":"2005","journal-title":"International Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0086|cit86","first-page":"466","article-title":"A case report of respiratory muscle paralysis caused by matrine","volume":"2","author":"Gong","year":"2000","journal-title":"Lishizhen Medicine and Materia Medica Research"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0087|cit87","unstructured":"GRADE Working Group GRADE handbook for grading quality of evidence and strength of recommendations, 2013 guidelinedevelopment.org\/handbook"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0088|cit88","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0089|cit89","first-page":"61","article-title":"Allergic drug eruption caused by Kushensu","volume":"17","author":"Gu","year":"2008","journal-title":"Chinese Journal of Pharmacoepidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines: 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence - publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence - inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence - indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD013106.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jclinepi.2017.05.005","article-title":"GRADE guidelines: 17. Assessing the risk of bias associated with missing participant outcome data in a body of evidence","volume":"87","author":"Guyatt","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"issue":"20","key":"10.1002\/14651858.CD013106.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0104|cit104","first-page":"944","article-title":"Lamivudine matrine combination therapy for chronic hepatitis B: a systematic review","volume":"24","author":"He","year":"2013","journal-title":"Lishizhen Medicine and Materia Medica Research"},{"issue":"11","key":"10.1002\/14651858.CD013106.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD013106.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0107|cit107","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7150\/ijms.2.50","article-title":"Epidemiology and prevention of hepatitis B virus infection","volume":"2","author":"Hou","year":"2005","journal-title":"International Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0109|cit109","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting E2A www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0110|cit110","unstructured":"International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH harmonised guideline. Integrated Addendum to ICH E6(R1): guideline for good clinical practice E6(R2) www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e28422","DOI":"10.1371\/journal.pone.0028422","article-title":"Statistical multiplicity in systematic reviews of anaesthesia interventions: a quantification and comparison between Cochrane and non-Cochrane reviews","volume":"6","author":"Imberger","year":"2011","journal-title":"Plos One"},{"issue":"9912","key":"10.1002\/14651858.CD013106.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0140-6736(13)62227-8","article-title":"Increasing value and reducing waste in research design, conduct, and analysis","volume":"383","author":"Ioannidis","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"9","key":"10.1002\/14651858.CD013106.pub2-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012143.pub3","article-title":"Direct-acting antivirals for chronic hepatitis C","author":"Jakobsen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"361","key":"10.1002\/14651858.CD013106.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"k1382","DOI":"10.1136\/bmj.k1382","article-title":"Do direct acting antivirals cure chronic hepatitis C?","volume":"10","author":"Jakobsen","year":"2018","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"35","key":"10.1002\/14651858.CD013106.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13350","article-title":"Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation","volume":"13","author":"Jones","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e25854","DOI":"10.5812\/hepatmon.15(4)2015.25854","article-title":"Economic burden of hepatitis B virus-related diseases: evidence from Iran","volume":"15","author":"Keshavarz","year":"2015","journal-title":"Hepatitis Monthly"},{"issue":"11","key":"10.1002\/14651858.CD013106.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1590\/S0102-695X2012005000043","article-title":"A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Febaceae","volume":"22","author":"Krishna","year":"2012","journal-title":"Brazilian Journal of Pharmacognosy"},{"issue":"24","key":"10.1002\/14651858.CD013106.pub2-BIB0121|cit121","first-page":"50","article-title":"Lamivudine in combination with matrine for chronic hepatitis B","volume":"13","author":"Lai","year":"2015","journal-title":"Journal of Community Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004790.pub2","article-title":"Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers","author":"Lee","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0123|cit123","first-page":"149","article-title":"Epidemiological characteristics of adverse reaction of oxymatrine on database analyze","volume":"1","author":"Li","year":"2011","journal-title":"Anti-tumor Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0124|cit124","first-page":"124","article-title":"One case of allergic shock caused by oxymatrine glucose injection","volume":"34","author":"Li","year":"2015","journal-title":"Journal of Pharmaceutical Research"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0125|cit125","first-page":"500","article-title":"Matrine for treatment of carcinoma","volume":"38","author":"Li","year":"2017","journal-title":"International Journal of Laboratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013089.pub2","article-title":"Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B","author":"Liang","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013106.pub2-BIB0127|cit127","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013106","article-title":"Radix Sophorae flavescentis versus antiviral drugs for chronic hepatitis B","author":"Liang","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013106.pub2-BIB0128|cit128","first-page":"801","article-title":"Advance in the pharmacological research on matrine","volume":"28","author":"Liu","year":"2003","journal-title":"China Journal of Chinese Materia Medica"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1142\/S0192415X03001107","article-title":"Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials","volume":"31","author":"Liu","year":"2003","journal-title":"American Journal of Chinese Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0130|cit130","first-page":"69","article-title":"Efficacy of intramuscular matrine in the treatment of chronic hepatitis B","volume":"3","author":"Long","year":"2004","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"issue":"33","key":"10.1002\/14651858.CD013106.pub2-BIB0131|cit131","first-page":"483","article-title":"Telbivudine in combination with matrine injection for treating chronic hepatitis B","volume":"10","author":"Lu","year":"2012","journal-title":"Guide of China Medicine"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1472-6963-13-37","article-title":"Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China","volume":"13","author":"Lu","year":"2013","journal-title":"BMC Health Services Research"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9912","key":"10.1002\/14651858.CD013106.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0140-6736(13)62329-6","article-title":"Biomedical research: increasing value, reducing waste","volume":"383","author":"Macleod","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2016.10.031","article-title":"Prognosis of patients with chronic hepatitis B in France (2008-2013): a nationwide, observational and hospital-based study","volume":"66","author":"Mallet","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"22","key":"10.1002\/14651858.CD013106.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.3748\/wjg.v10.i22.3269","article-title":"Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study","volume":"10","author":"Mao","year":"2004","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0137|cit137","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Churchill R Methodological Expectations of Cochrane Intervention Reviews, Version 1.07, 2018 community.cochrane.org\/mecir-manual"},{"issue":"9128","key":"10.1002\/14651858.CD013106.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"9263","key":"10.1002\/14651858.CD013106.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"10027","key":"10.1002\/14651858.CD013106.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0140-6736(15)00307-4","article-title":"Increasing value and reducing waste in biomedical research: who's listening?","volume":"387","author":"Moher","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD013106.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"736-42; quiz 74","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clinthera.2008.02.012","article-title":"Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study","volume":"30","author":"Pellicelli","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00042560-200007010-00003","article-title":"Mortality for liver disease in patients with HIV infection: a cohort study","volume":"24","author":"Puoti","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"15","key":"10.1002\/14651858.CD013106.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.11569\/wcjd.v21.i15.1432","article-title":"Entecavir plus matrine vs entecavir monotherapy for HBeAg-positive chronic hepatitis B: a meta-analysis","volume":"21","author":"Qi","year":"2013","journal-title":"World Chinese Journal of Digestology"},{"issue":"3","key":"10.1002\/14651858.CD013106.pub2-BIB0146|cit146","first-page":"61","article-title":"Summary of research on anticancer mechanism of constituent matrine","volume":"8","author":"Qin","year":"2009","journal-title":"Journal of Shenzhen Polytechnic"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0147|cit147","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"35","key":"10.1002\/14651858.CD013106.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16350","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies","volume":"16","author":"Savovi\u0107","year":"2012","journal-title":"Health Technology Assessment"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/aje\/kwx344","article-title":"Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: the ROBES meta-epidemiologic study","volume":"187","author":"Savovi\u0107","year":"2018","journal-title":"American Journal of Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jclinepi.2016.03.018","article-title":"Interpreting GRADE's levels of certainty or quality of the evidence: GRADE for statisticians, considering review information size or less emphasis on imprecision?","volume":"75","author":"Sch\u00fcnemann","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013106.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3310\/hta13suppl3\/05","article-title":"Entecavir for the treatment of chronic hepatitis B infection","volume":"13","author":"Shepherd","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11655-015-2143-0","article-title":"Oral oxymatrine preparation for chronic hepatitis B: a systematic review of randomized controlled trials","volume":"22","author":"Song","year":"2016","journal-title":"Chinese Journal of Integrative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013106.pub2-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012069.pub2","article-title":"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies","author":"Storeb\u00f8","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2331554","article-title":"The probable error of a mean","volume":"6","author":"Student","year":"1908","journal-title":"Biometrika"},{"issue":"18","key":"10.1002\/14651858.CD013106.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0159|cit159","first-page":"326","article-title":"The extract of roots of Sophora flavescens enhances the recovery of motor function by axonal growth in mice with a spinal cord injury","volume":"6","author":"Tanabe","year":"2015","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0160|cit160","first-page":"57","article-title":"Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals","volume":"2","author":"Thorlund","year":"2010","journal-title":"Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0161|cit161","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User manual for Trial Sequential Analysis (TSA), 2011 ctu.dk\/tsa\/files\/tsa_manual.pdf"},{"issue":"10","key":"10.1002\/14651858.CD013106.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"e25491","DOI":"10.1371\/journal.pone.0025491","article-title":"The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study","volume":"6","author":"Thorlund","year":"2011","journal-title":"PloS One"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013106.pub2-BIB0163|cit163","first-page":"S1","article-title":"Overview of viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0164|cit164","unstructured":"Copenhagen Trial Unit TSA - Trial Sequential Analysis 2011"},{"issue":"15","key":"10.1002\/14651858.CD013106.pub2-BIB0165|cit165","first-page":"195","article-title":"Clinical analysis of entecavir combined with Kushensu in treatment of chronic hepatitis B","volume":"7","author":"Wang","year":"2015","journal-title":"China Continuing Medical Education"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Wang HL Lu X Yang X Xu N Antiviral therapy in lamivudine-resistant chronic hepatitis B patients: a systematic review and network meta-analysis Gastroenterology Research and Practice 2016 3435965","DOI":"10.1155\/2016\/3435965"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0167|cit167","first-page":"2478","article-title":"Lamivudine versus kushenin for chronic hepatitis B and YMDD mutation: a systematic review and meta-analysis","volume":"43","author":"Wang","year":"2016","journal-title":"Liaoning Journal of Traditional Chinese Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ptr.5808","article-title":"The clinical efficacy and adverse effects of interferon combined with matrine in chronic hepatitis B: a systematic review and meta-analysis","volume":"31","author":"Wang","year":"2017","journal-title":"Phytotherapy Research"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0172|cit172","unstructured":"World Health Organization Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection apps.who.int\/iris\/bitstream\/10665\/154590\/1\/9789241549059_eng.pdf?ua=1&ua=1"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0173|cit173","unstructured":"World Health Organization Global hepatitis report, 2017 www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0174|cit174","unstructured":"World Health Organization Hepatitis B fact sheets www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"issue":"7644","key":"10.1002\/14651858.CD013106.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0176|cit176","volume-title":"Sophorus Species for Chronic Hepatitis B and Viremic Carrier: a Systematic Review of Randomized Clinical Trials [Dissertation thesis]","author":"Wu","year":"2011"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008960.pub2","article-title":"Phyllanthus species for chronic hepatitis B virus infection","author":"Xia","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009004.pub2","article-title":"Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection","author":"Xia","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"10.1002\/14651858.CD013106.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3748\/wjg.v16.i16.2028","article-title":"Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro","volume":"16","author":"Xu","year":"2010","journal-title":"World Journal of Gastroenterology"},{"issue":"34","key":"10.1002\/14651858.CD013106.pub2-BIB0180|cit180","first-page":"60","article-title":"Entecavir in combination with Kushensu for treating HBeAg positive chronic hepatitis B","volume":"4","author":"Yin","year":"2011","journal-title":"Clinical Rational Drug Use"},{"issue":"2","key":"10.1002\/14651858.CD013106.pub2-BIB0181|cit181","first-page":"183","article-title":"Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats","volume":"22","author":"Zhang","year":"2001","journal-title":"Acta Pharmacologica Sinica"},{"issue":"4","key":"10.1002\/14651858.CD013106.pub2-BIB0182|cit182","first-page":"635","article-title":"One case of fever induced by 0.6% oxymatrine salt water injection","volume":"9","author":"Zhang","year":"2008","journal-title":"Clinical Journal of Medical Officer"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0183|cit183","first-page":"935","article-title":"Combined application of oxymatrine and lamivudine in treating 62 cases of chronic hepatitis B","volume":"19","author":"Zhang","year":"2012","journal-title":"Clinical Medical Engineering"},{"key":"10.1002\/14651858.CD013106.pub2-BIB0184|cit184","volume-title":"Chinese Materia Medica-Chemistry, Pharmacology and Applications","author":"Zhu","year":"1998"},{"issue":"6","key":"10.1002\/14651858.CD013106.pub2-BIB0185|cit185","first-page":"592","article-title":"Composite Sophorae injection in prevention of toxicity and adverse effects caused by chemotherapeutic agents","volume":"24","author":"Zhu","year":"2009","journal-title":"Journal of Practical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013106.pub2-BIB0186|cit186","first-page":"1757","article-title":"Preparation process of matrine and glucose injection","volume":"12","author":"Zou","year":"2009","journal-title":"China Pharmacist"},{"issue":"8","key":"10.1002\/14651858.CD013106.pub2-BIB0187|cit187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013106","article-title":"Radix Sophorae flavescentis versus antiviral drugs for chronic hepatitis B","author":"Liang","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013106.pub2-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008957","article-title":"Sophorus species for chronic hepatitis B virus infection","author":"Wu","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013106.pub2-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008957.pub2","article-title":"Sophorus species for chronic hepatitis B virus infection","author":"Wu","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013106.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:14:55Z","timestamp":1628536495000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD013106.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":189,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013106.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]}}}